Literature DB >> 12735912

Withdrawal of levodopa and other risk factors for malignant syndrome in Parkinson's disease.

Takao Hashimoto1, Takahiko Tokuda, Norinao Hanyu, Kenichi Tabata, Nobuo Yanagisawa.   

Abstract

A symptom complex identical to neuroleptic malignant syndrome (MS) is known to develop in patients with idiopathic Parkinson's disease (PD) or other forms of parkinsonism on long-term treatment with anti-parkinsonian drugs. In order to clarify the risk factors for parkinsonian MS, the authors retrospectively reviewed charts of consecutive inpatients with PD in the neurological departments at the three hospitals and found 16 episodes of parkinsonian MS in 14 patients. A survey of health status preceding MS disclosed that deterioration of parkinsonian symptoms alone may induce MS, while association of major risk factors, i.e. rapid discontinuation of anti-parkinsonian drugs, dehydration or infection may precipitate or exacerbate MS. Cerebral vascular disorders, mechanical brain injury or physiological stress could be other risk factors leading to MS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12735912     DOI: 10.1016/s1353-8020(02)00119-0

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  7 in total

1.  Parkinsonism-hyperpyrexia syndrome: Broadening our differential diagnosis in the ICU.

Authors:  Sara Hocker; Daniel L Kenney; Kannan Ramar
Journal:  Neurol Clin Pract       Date:  2013-12

Review 2.  Management of the hospitalized patient with Parkinson's disease: current state of the field and need for guidelines.

Authors:  Michael J Aminoff; Chad W Christine; Joseph H Friedman; Kelvin L Chou; Kelly E Lyons; Rajesh Pahwa; Bastian R Bloem; Sotirios A Parashos; Catherine C Price; Irene A Malaty; Robert Iansek; Ivan Bodis-Wollner; Oksana Suchowersky; Wolfgang H Oertel; Jorge Zamudio; Joyce Oberdorf; Peter Schmidt; Michael S Okun
Journal:  Parkinsonism Relat Disord       Date:  2010-12-14       Impact factor: 4.891

3.  Rotenone-induced energy stress decompensated in ventral mesocerebrum is associated with Parkinsonism progression in rats.

Authors:  Qunhua Bai; Junlin He; Yong Tang; Shibo Wang; Jingfu Qiu; Yang Wang; Chao Yu
Journal:  Exp Ther Med       Date:  2016-05-18       Impact factor: 2.447

Review 4.  The parkinsonism-hyperpyrexia syndrome.

Authors:  Edward J Newman; Donald G Grosset; Peter G E Kennedy
Journal:  Neurocrit Care       Date:  2008-08-20       Impact factor: 3.210

5.  Neuroleptic malignant-like syndrome with a slight elevation of creatine-kinase levels and respiratory failure in a patient with Parkinson's disease.

Authors:  Li Wei; Yinghui Chen
Journal:  Patient Prefer Adherence       Date:  2014-02-27       Impact factor: 2.711

6.  Neuroleptic malignant-like syndrome associated multiple system atrophy: report on three cases.

Authors:  Yan Lin; Lin Ma; Nan Zhang; Ruihua Li; Wenjing Jiang
Journal:  BMC Neurol       Date:  2022-02-25       Impact factor: 2.474

Review 7.  Extended-release oral capsule of carbidopa-levodopa in Parkinson disease.

Authors:  Jason Margolesky; Carlos Singer
Journal:  Ther Adv Neurol Disord       Date:  2017-10-30       Impact factor: 6.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.